MD TP24: Validation of anti-migratory, anti-stimulatory and anti-apoptotic effects of neutrophil signaling

Pemphigoid diseases are characterized by autoantibodies against structural proteins of the dermal-epidermal junction. Release of reactive oxygen species (ROS) from antibody-binding neutrophils has been shown to play a role in the pathogenesis of blister formation and tissue damage. Current therapy strategies rely on general immunosuppression which does not always lead to remission.

ROS release can be inhibited by drugs that target intracellular signaling pathways. The effects of the inhibitors for split formation at the dermal-epidermal junction, the expression of surface molecules and migration behavior of neutrophils will be tested. With this we want to evaluate possible therapeutic targets for the treatment of pemphigoid diseases